epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Alopecia areata

OVERVIEW

  • Highlights & Basics
  • Images

DIAGNOSIS

  • Diagnostic Approach
  • Risk Factors
  • History & Exam
  • Tests
  • Differential Diagnosis
  • Criteria
  • Screening

TREATMENT

  • Tx Approach
  • Tx Options
  • Emerging Tx
  • Prevention

FOLLOW-UP

  • Overview
  • Complications

REFERENCES

  • Citations
  • Guidelines
  • Credits

PATIENT RESOURCES

  • Patient Instructions

Highlights & Basics

AAFont SizeShareMore Information
Key Highlights
  • Alopecia areata is an autoimmune disease that targets the hair follicle.

  • It is characterized by sudden onset of patchy hair loss.

  • The diagnosis is clinical. Characteristic physical findings are exclamation point hairs (short, broken hairs tapering proximally at the scalp) and a positive pull test. A scalp biopsy shows perifollicular inflammation.

  • Topical or intralesional corticosteroids are appropriate for patients with limited hair loss. Skin atrophy can be a temporary side effect.

Alopecia areata
Alopecia areata
Provided by Paradi Mirmirani, MD

Quick Reference

  • History & Exam

    • Key Factors

      • Other Factors

        More information...
      • Diagnostics Tests

          More information...
        • Treatment Options

            More information...

          Definition

          Epidemiology

          Etiology

          Pathophysiology

          content by BMJ Group
          Last updated

          Images

          • Alopecia areata

            Alopecia areata

          • Hair pull test

            Hair pull test

          • Nail pitting in alopecia areata

            Nail pitting in alopecia areata

          Citations

            Key Articles

            • Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines: part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440-447.[Abstract]

            • Hordinsky MK. Medical treatment of noncicatricial alopecia. Semin Cutan Med Surg. 2006;25:51-55. [Abstract]

            • Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916-926.[Abstract]

            Other Online Resources

            • National Alopecia Areata Foundation

            Referenced Articles

            • 1. Simakou T, Butcher JP, Reid S, et al. Alopecia areata: A multifactorial autoimmune condition. J Autoimmun. 2019 Mar;98:74-85.[Abstract][Full Text]

            • 2. Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: An Australian expert consensus statement. Australas J Dermatol. 2019 May;60(2):163-170.[Abstract][Full Text]

            • 3. Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines: part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440-447.[Abstract]

            • 4. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397-403.[Abstract][Full Text]

            • 5. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628-633.[Abstract]

            • 6. Price VH. Treatment of hair loss. N Engl J Med. 1999;341:964-973. [Abstract]

            • 7. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549-566.[Abstract]

            • 8. Hordinsky MK. Medical treatment of noncicatricial alopecia. Semin Cutan Med Surg. 2006;25:51-55. [Abstract]

            • 9. Norris D. Alopecia areata: current state of knowledge. J Am Acad Dermatol. 2004;51:S16-S17. [Abstract]

            • 10. Green J, Sinclair RD. Genetics of alopecia areata. Australas J Dermatol. 2000;41:213-218.[Abstract]

            • 11. Gilhar A, Ullmann Y, Berkutzki T, et al. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest. 1998;101:62-67. [Abstract]

            • 12. Darwin E, Hirt PA, Fertig R, et al. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology. 2018 Mar-Apr;10(2):51-60.[Abstract][Full Text]

            • 13. Colombe BW, Price VH, Khoury EL, et al. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol. 1995;33:757-764.[Abstract]

            • 14. Martinez-Mir A, Zlotogorski A, Gordon D, et al. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet. 2007;80:316-328.[Abstract]

            • 15. McDonagh AJG, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27:405-409.[Abstract]

            • 16. Goh C, Finkel M, Christos PJ, et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055-1060. [Abstract]

            • 17. Han A, Mirmirani P. Clinical approach to the patient with alopecia. Semin Cutan Med Surg. 2006;25:11-23. [Abstract]

            • 18. Tosti A, Torres F. Dermoscopy in the diagnosis of hair and scalp disorders. Actas Dermosifiliogr. 2009;100(suppl 1):114-119.[Abstract]

            • 19. Stein DJ, Hollander E. Dermatology and conditions related to obsessive-compulsive disorder. J Am Acad Dermatol. 1992;26:237-242. [Abstract]

            • 20. Eudy G, Solomon AR. The histopathology of noncicatricial alopecia. Semin Cutan Med Surg. 2006;25:35-40.[Abstract]

            • 21. Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916-926.[Abstract]

            • 22. Khoury EL, Price VH, Abdel-Salam MM, et al. Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. J Invest Dermatol. 1992;99:40-47.[Abstract]

            • 23. Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol. 1996;35:133-136. [Abstract]

            • 24. King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022 May 5;386(18):1687-99.[Abstract]

          Have feedback?
          Tell us about your experience
          Scroll to Top
          epocrates logo

          Sign in to access our clinical decision support tools

          Sign inCreate Account
          Download Epocrates from the App StoreDownload Epocrates from the Play Store
          About UsFeaturesBusiness SolutionsHelp & Feedback
          © 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information